NCT01553721

Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

A Placebo-controlled, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a placebo-controlled, double-blind, phase II clinical study to evaluate the efficacy and safety of Udenafil in patient with Pulmonary Arterial Hypertension(PAH).

Conditions

• Pulmonary Arterial Hypertension

Interventions

Type	Name	Description
DRUG	udenafil	Phase IIa - Udenafil Dose 1, Dose 2(Single dose) Phase IIb - Udenafil(BID)
DRUG	placebo	Phase IIa - placebo Phase IIb - placebo

Timeline

• Start date: 2011-08-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2012-03-14
• Last updated: 2016-04-18

Locations

9 sites across 1 country: South Korea